David J. Straus

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy et al. · Journal of Clinical Oncology · 2004 · 579 citations

Medicine, Hematology, Pharmacology +17

On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data

Jeffrey J. Gaynor, Eric J. Feuer, Claire C. Tan et al. · Journal of the American Statistical Association · 1993 · 480 citations

Public Health, Biostatistics, Oncology +17

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz et al. · Blood · 2001 · 427 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer et al. · Blood · 2004 · 406 citations · Full text

Medicine, Immunology, Pharmacotherapy +12